biox webcast is up, page-25

Hi brainybull,

As I understand it, the can2 cohort had to have progression or imminent progression reversed or prevented and this occurred in 4 out of 21.

Can3 cohort are all in remission and so I take it are less 'challenging' insofar as CVAC does not have to reverse or halt an active course of the disease, but sustain an existing state of the 'cessation of progression', if that is an accurate way to describe the difference (not a medical person).

The halting of progress found to some degree in the little IIa trial is certainly a good thing, but I am not aware of another step involving outright 'cure' ever being the goal, or within scope of the treatment. Just a significant increase in the length and stability of remission after other treatments. Happy to be corrected.


cheers